Skip to main content
Journal cover image

The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.

Publication ,  Journal Article
Assimon, MM; Pun, PH; Al-Khatib, SM; Brookhart, MA; Gaynes, BN; Winkelmayer, WC; Flythe, JE
Published in: Nephrol Dial Transplant
October 19, 2022

BACKGROUND: Hypokalemia is a risk factor for drug-induced QT prolongation. Larger serum-to-dialysate potassium gradients during hemodialysis (HD) may augment the proarrhythmic risks of selective serotonin reuptake inhibitors (SSRIs). METHODS: We conducted a cohort study using 2007-2017 data from the United States Renal Data System and a large dialysis provider to examine if the serum-to-dialysate potassium gradient modifies SSRI cardiac safety. Using a new-user design, we compared 1-year sudden cardiac death (SCD) risk among HD patients newly treated with higher (citalopram, escitalopram) versus lower (fluoxetine, fluvoxamine, paroxetine, sertraline) QT-prolonging potential SSRIs, overall and stratified by baseline potassium gradient (≥4 versus <4 mEq/l). We used inverse probability of treatment-weighted survival models to estimate weighted hazard ratios (HRs) and 95% confidence intervals (CIs) and conducted a confirmatory nested case-control study. RESULTS: The study included 25 099 patients: 11 107 (44.3%) higher QT-prolonging potential SSRI new users and 13 992 (55.7%) lower QT-prolonging potential SSRI new users. Overall, higher versus lower QT-prolonging potential SSRI use was not associated with SCD [weighted HR 1.03 (95% CI 0.86-1.24)]. However, a greater risk of SCD was associated with higher versus lower QT-prolonging potential SSRI use among patients with baseline potassium gradients ≥4 mEq/l but not among those with gradients <4 mEq/l [weighted HR 2.17 (95% CI 1.16-4.03) versus 0.95 (0.78-1.16)]. Nested case-control analyses yielded analogous results. CONCLUSIONS: The serum-to-dialysate potassium gradient may modify the association between higher versus lower QT-prolonging SSRI use and SCD among people receiving HD. Minimizing the potassium gradient in the setting of QT-prolonging medication use may be warranted.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Nephrol Dial Transplant

DOI

EISSN

1460-2385

Publication Date

October 19, 2022

Volume

37

Issue

11

Start / End Page

2241 / 2252

Location

England

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Sertraline
  • Selective Serotonin Reuptake Inhibitors
  • Renal Dialysis
  • Potassium
  • Paroxetine
  • Humans
  • Fluvoxamine
  • Fluoxetine
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Assimon, M. M., Pun, P. H., Al-Khatib, S. M., Brookhart, M. A., Gaynes, B. N., Winkelmayer, W. C., & Flythe, J. E. (2022). The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. Nephrol Dial Transplant, 37(11), 2241–2252. https://doi.org/10.1093/ndt/gfac214
Assimon, Magdalene M., Patrick H. Pun, Sana M. Al-Khatib, Maurice Alan Brookhart, Bradley N. Gaynes, Wolfgang C. Winkelmayer, and Jennifer E. Flythe. “The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.Nephrol Dial Transplant 37, no. 11 (October 19, 2022): 2241–52. https://doi.org/10.1093/ndt/gfac214.
Assimon MM, Pun PH, Al-Khatib SM, Brookhart MA, Gaynes BN, Winkelmayer WC, et al. The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. Nephrol Dial Transplant. 2022 Oct 19;37(11):2241–52.
Assimon, Magdalene M., et al. “The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study.Nephrol Dial Transplant, vol. 37, no. 11, Oct. 2022, pp. 2241–52. Pubmed, doi:10.1093/ndt/gfac214.
Assimon MM, Pun PH, Al-Khatib SM, Brookhart MA, Gaynes BN, Winkelmayer WC, Flythe JE. The modifying effect of the serum-to-dialysate potassium gradient on the cardiovascular safety of SSRIs in the hemodialysis population: a pharmacoepidemiologic study. Nephrol Dial Transplant. 2022 Oct 19;37(11):2241–2252.
Journal cover image

Published In

Nephrol Dial Transplant

DOI

EISSN

1460-2385

Publication Date

October 19, 2022

Volume

37

Issue

11

Start / End Page

2241 / 2252

Location

England

Related Subject Headings

  • Urology & Nephrology
  • United States
  • Sertraline
  • Selective Serotonin Reuptake Inhibitors
  • Renal Dialysis
  • Potassium
  • Paroxetine
  • Humans
  • Fluvoxamine
  • Fluoxetine